On 06 de nov. de 2025, GMED reported earnings of 1.18 USD per share (EPS) for Q3 25, beating the estimate of 0.79 USD, resulting in a 47.80% surprise. Revenue reached 769.05 milhão, compared to an expected 749.03 milhão, with a 2.67% difference. The market reacted with a +35.94% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analistas forecast an EPS of 1.11 USD, with revenue projected to reach 792.89 milhão USD, implying an diminuir of -5.93% EPS, and aumentar of 3.10% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AngioDynamics, Inc.
Report Date
06 de jan. de 2026 Para Q2 26
Estimativa
-$0.10
Real
$0.00
Surpresa
+100.00%
FAQ
What were GLOBUS MEDICAL INC's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, GLOBUS MEDICAL INC reported EPS of $1.18, beating estimates by 47.8%, and revenue of $769.05M, 2.67% above expectations.
How did the market react to GLOBUS MEDICAL INC's Q3 2025 earnings?
The stock price moved up 35.94%, changed from $61.71 before the earnings release to $83.89 the day after.
When is GLOBUS MEDICAL INC expected to report next?
The next earning report is scheduled for 10 de fev. de 2026.
What are the forecasts for GLOBUS MEDICAL INC's next earnings report?
Based on 17
analistas, GLOBUS MEDICAL INC is expected to report EPS of $1.11 and revenue of $792.89M for Q4 2025.